VKTX
Viking Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.82B
P/E Ratio
—
EPS
$-3.19
Beta
0.82
52W High
$43.15
52W Low
$22.96
50-Day MA
$33.45
200-Day MA
$32.76
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
-0.03
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -47.30% |
| Return on Assets | -30.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.57 |
| Price-to-Book | 5.98 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -71.64 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $115.89M |
| Float | $112.74M |
| % Insiders | 2.81% |
| % Institutions | 63.02% |
Historical Volatility
HV 10-Day
34.47%
HV 20-Day
48.99%
HV 30-Day
55.70%
HV 60-Day
61.36%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($92.72 target)
5
Strong Buy12
Buy2
HoldData last updated: 4/28/2026